We describe a young woman with primary adrenal insufficiency, hypoparathyroidism (autoinmmune polyglandular syndrome type 1), Graves disease, vitiligo, and alopecia universalis. Five years after the diagnosis, she presented with recurrent ophthalmological and neurological disorders as features of Vogt-KoyanagiHarada syndrome. A marked therapeutic response was noted on systemic high-dose corticosteroid treatment. To the best of our knowledge, such a spectre of autoimmune diseases has not been reported previously.
The Vogt-Koyanagi-Harada syndrome is a rare, but well documented clinical entity with probably cell-mediated autoimmune pathogenesis, marked by ocular, dermatological and neurological disorders of variable severity. The American Uveitis Society' established diagnostic criteria (box 1) in 1980.
Primary adrenal insufficiency, chronic mucocutaneous candidiasis and hypoparathyroidism define the autoimmune polyglandular syndrome type 1. Primary gonadal failure, vitiligo, alopecia, pernicious anemia, insulindependent diabetes, hypothyroidism, keratopathy, periodic malabsorption, chronic hepatitis and hypoplasia of dental enamel, nails, and tympanic membranes can be included.2 Case report In 1988, a 20-year-old woman was admitted with a history of increasing fatigue, nausea and gradual, but complete, loss of body hair since the age of 18 years. After menarche at the age of 15 years, she menstruated four or five times yearly and had no pregnancy. There was a fiveyear history of vitiligo. No history of endocrine disease among the patient's relatives was elicited. Examination revealed a warm pale skin, alopecia universalis, numerous patches of vitiligo and no sign of mucocutaneous candidiasis. Dental caries was extended. When supine, the pulse was 120 beats/min and blood pressure was 90/60 mmHg.
Investigations suggested adrenal insufficiency (box 2), which was confirmed by low plasma cortisol after intravenous administration of adrenocorticotropin, low plasma aldosterone and high plasma renin activity levels. A high free thyroxine and low thyroid-stimulating hormone after intravenous thyrotropin-releasing hormone stimulation (0.2 mg) revealed thyrotoxicosis. Scintiscan and ultrasound examination confirmed a small goitre. Hormone measurements are shown in the table. Shortly after introduction of hydrocortisone and methimazole therapy, serum calcium levels decreased to normal. Three months later, normal plasma thyroxine and cortisol were maintained on therapy and fludrocortisone was added. Menstrual cycles became regular, the ionized calcium level was 0.96 mmolIl (1. Adrenal antibodies are positive even seven years after the onset of Addison's disease, which is not an unusual finding in this syndrome.' Low plasma aldosterone levels also suggest an autoimmune origin.',6 Persistence of thyroid antibodies may reflect a continuing autoimmune process. Existence of steroid cell antibodies in Addison's disease strongly correlates with concurrent ovarian failure. 6 The importance of parathyroid antibody detection in autoimmune polyglandular syndrome is less clear4 since there is no significant prevalence even in idiopathic hypoparathyroidism. Melanocyte antibodies can only be detected in patients with vitiligo and autoimmune polyglandular syndrome type 17 It would be interesting to examine the serum of our patient for these antibodies, especially as she does not have hyperpigmented skin but does have VogtKoyanagi-Harada syndrome. It might be that melanocyte antibodies are responsible for the highly variable presentation of hyperpigmentation reported in autoimmune polyglandular syndrome type 1.4 Since vitiligo occured before uveitis was diagnosed, it was difficult to confirm the additional effects ofVogt-Koyanagi-Harada syndrome on the course of the lesion.5 The response to Candida albicans skin test is often absent in autoimmune polyglandular syndrome type 1, as in this case.
Ophthalmological, dermatological and neurological findings were compatible with a diagnosis of Vogt-Koyanagi-Harada syndrome, which was confirmed by complementary investigations. A unifying mechanism for its diverse clinical manifestations affecting central nervous system, eye, integument and auditory system has not been found, although an autoimmune process was suggested. The link with HLA in autoimmune polyglandular syndrome type 1 has not been confirmed except in a small subset of patients with increased HLA-A antigens. 10 The presence of HLA DR4 and HLA DRw52 DRw53 haplotype may indicate susceptibility to VogtKoyanagi-Harada syndrome, but may not represent specific tissue involvement or determine the prognosis.9 Vitiligo was also strongly associated with HLA DR4.
The onset of Vogt-Koyanagi-Harada syndrome was masked by high doses of corticosteroids. On dose reduction the full picture was seen and recognised as a cause of the adrenocortical crisis. Although patients with VogtKoyanagi-Harada syndrome have limited therapeutic options, this finding supports the choice of early, pulse and high-dose systemic therapy in its treatment. It is of therapeutic and clinical interest to detect such associations of autoimmune diseases. 
